the next great thing is already here, page-81

Correct combi,

We are still sitting at L/T 3 year support levels... perhaps days like today are simply about a couple of retailers beginning to factor in some of the old news...

With the sellers MD looking the way it currently is, the re-rating is going to see a swift and sharp rise in sp... well overdue, imo.

We are all aware that news should not be too far away now, but the big question remains... from which direction will that news arrive... that's anyone's guess...?

"OBJ is in discussions with five of the world’s largest Consumer Healthcare companies across a variety of applications"

"...the fast moving consumer goods company will be granted a licence for each product and receive royalties for five years or life of patent, whichever was longer."

"OBJ is working closely with two of the world's foremost cosmetic brands"

"significant expansion to IP and Patent portfolios with applications covering the commercial areas of interest to OBJs partner companies"

"working with one of the worlds largest pharmaceutical companies in consumer acceptance testing for a patch version of an existing multi-billion dollar product currently sold internationally"

"During 2012 OBJ became a technology partner to the world's largest Pharmaceutical Company..."

"The announcement of the JDA with P&G and the expansion of programs with GSK, were major accomplishments for the period."

"...5 year Strategic Alliance for the design and development of a wide range of consumer products"

"Global FMCG Company to Secure Access Rights"

"GSK has reported commercially and statistically significant levels of enhancement"

"commences multi-product discussions with major US Pharma"

"3M remains a major collaborator with OBJ"

"The Company’s ability to demonstrate the benefit of its magnetic micro-array technologies grew further during 2012 with the development of new and refined testing methodologies. During the period, the Company showed partner companies commercially significant levels of product performance enhancement in the Oral health, cosmetic, skin care, analgesic, pharmaceutical and industrial fields."

GSK

August 2012
In 2012 OBJ reported continuing successes in its exclusive collaboration with GSK Healthcare in the Caries (tooth decay) field. Highly encouraging ex vivo results expanded this exclusive program in March 2012 to also include
toothpaste ingredients in other sectors of the oral health.

OBJ's collaboration with GSK in the UK has now also expanded to GlaxoSmithKline Pharmaceutical division in the US.

18/02/2010: GSK enters into further agreement with OBJ
25/10/2010: GSK to Progress FIM Technology
17/05/2011: Collaborative Development Agreement with GSK
??/??/2013: GSK...?

P&G

December 2012
OBJ announces key milestone and solid investment by The Procter and Gamble Company which has committed to two separate human clinical trials due to commence early in 2013 following successful pre-clinical developments conducted as part of the exclusive multiproduct Joint Development Agreement (JDA) with OBJ as announced on 18 May 2012.

OBJ is working with P&G's to enhance the performance levels across a wide range of products representing P&G's 50 Leadership Brands - Some of the world's most recognised household names in the market today - ie, products are already approved so clinical trials are not required for safety or efficacy reasons - Trials are being conducted for marketing claims with a clear objective of taking OBJ’s technologies to market in P&G products.

These first two fully funded clinical trials will be conducted at P&G facilities in the US and South East Asia while a second program involving a new P&G nominated molecule has already entered into development by OBJ's R&D team.

Imo, during 2013 OBJ s/holders may have a difficult task in keeping up with the number of clinical trial underway.
Cost to OBJ Limited: $0.00 ;)

October 2011
Global FMCG Company to secure Access Rights for Beauty Care
"In September 2010, the Company entered into a Strategic Alliance with a global FMCG company to explore applications for the Company’s technologies across a wide range of consumer product platforms. The technical evaluation undertaken under this agreement required OBJ to develop magnetic micro-arrays that demonstrated enhanced delivery of a number of key ingredient molecules used in the FMCG product portfolios."

October 2012
P&G Earnings Call Transcript - CFO Jon Moeller
We have a large bundled initiatives coming across the Skin Care portfolio including Olay Total Effects CC cream, a restage of Olay Regenerist, the largest of the Olay Boutiques and the introduction of new mid tier boutique called Olay Fresh Effects which will be launched in January.

We'll also be introducing a new mid-tier hair care line price at 50-75 index to the base Pantene shampoos and conditioners. Our super premium Pantene Expert collection in our new mid-tier line will be available in January.

In the March quarter, we'll be launching the first innovation that spans multiple Male Blades and Razors brands including both Fusion Pro Glide (Inaudible) and is qualified to bring to market. But we're making good progress and are building an increasingly promising pipeline of category and brand creating innovations. - P&G Earnings Call Transcript

December 2012
Dermaportation Patent Allowed
We are advised that formal granting of the patent normally occurs in approximately 3 to 6 months. Dermaportation was the Company’s first drug delivery technology and has recently been incorporated into the e-Skin® cosmetic device system which is the subject of commercial discussions with a global skin care company.

???